# US 2017/0119870 A1 · Recombinant classical swine fever virus (csfv) comprising substitution in the tav epitope of the e2 protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0119870 A1
- Document ID: US20170119870A1
- Status: Published application
- Kind: A1
- Application number: 15/312,249
- Filed: 2015-05-22
- Published: 2017-05-04
- Earliest claimed: 2014-05-23
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Applicants: Boehringer Ingelheim Vetmedica GmbH
- Inventors: Gregor MEYERS; Sabine WIRTZ
- Web page: https://patentgrep.com/patent/US20170119870A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G01N 33/56983: {Viruses}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2770/24321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24362: by genetic engineering
- G01N 2333/185: Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates i.a. to a CSFV (classical swine fever virus) comprising a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45 of the E2 protein. Further, the present invention provides an immunogenic composition comprising the CSFV of the present invention and the use of the immunogenic composition for reducing the incidence of or severity in an animal of one or more clinical signs associated with CSF. Moreover, the present invention provides a method of differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.

## Claims

### Claim 1

A CSFV (classical swine fever virus) comprising a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45of the E2 protein.

### Claim 2 (depends on 1)

The CSFV according to claim 1, wherein said amino acid substitution is within the TAV epitope of the E2 protein having the amino acid sequence TAVSPTTLR.

### Claim 3 (depends on 1)

The CSFV according to claim 1, wherein said amino acid substitution within the TAV epitope of the E2 protein is a stable amino acid substitution.

### Claim 4 (depends on 1)

The CSFV according to claim 1, wherein the amino acid substitution within the TAV epitope of the E2 protein results in the TAV epitope sequence TAVSKDTLRT.

### Claim 5 (depends on 1)

The CSFV according to claim 1, wherein the amino acid substitution within the TAV epitope of the E2 protein results in a TAV epitope sequence as shown in SEQ ID NO: 22 or, wherein the CSFV has an amino acid as shown in SEQ ID NO: 3.

### Claim 6 (depends on 1)

The CSFV according to claim 1, wherein the CSFV is attenuated.

### Claim 7 (depends on 1)

The CSFV according to claim 1, wherein the CSFV has a mutation in the coding sequence for glycoprotein Erns and/or a mutation in the coding sequence for Npro, wherein the mutation in the coding sequence for glycoprotein Erns results in an inactivated RNase activity and wherein the mutation in the Npro coding sequence results in an non-functional Npro protein; preferably such mutation in the glycoprotein Erns is a deletion of amino acid at amino acid position 346 of glycoprotein Erns and the mutation in the coding sequence for Npro is a deletion of the Npro coding sequence except for the last two amino terminal amino acids.

### Claim 8 (depends on 1)

The CSFV according to claim 1, wherein the CSFV is a C (Chinese)-strain.

### Claim 9 (depends on 1)

A nucleic acid coding for a CSFV according claim 1, a vector comprising said nucleic acid.

### Claim 10 (depends on 1)

An immunogenic composition comprising the CSFV according claim 1.

### Claim 11 (depends on 10)

The immunogenic composition according to claim 10, wherein said immunogenic composition is a marker vaccine or a DIVA (differentiation between infected and vaccinated animals) vaccine.

### Claim 12 (depends on 10)

A method of reducing the incidence of or severity in an animal of one or more clinical signs associated with CSF, the method comprising the step of administering the immunogenic composition according to claim 10, wherein the reduction of the incidence of or the severity of the one or more clinical signs is relative to an animal not receiving the immunogenic composition.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more clinical signs are selected from the group consisting of: respiratory distress, labored breathing, coughing, sneezing, rhinitis, tachypnea, dyspnea, pneumonia, red/blue discolouration of the ears and vulva, jaundice, lymphocytic infiltrates, lymphadenopathy, hepatitis, nephritis, anorexia, fever, lethargy, agalatia, diarrhea, nasal extrudate, conjunctivitis, progressive weight loss, reduced weight gain, paleness of the skin, gastric ulcers, macroscopic and microscopic lesions on organs and tissues, lymphoid lesions, mortality, virus induced abortion, stillbirth, malformation of piglets, mummification and combinations thereof.

### Claim 14

A method of marking a CSFV vaccine comprising introducing a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45 of the E2 protein into a CSFV vaccine.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said amino acid substitution is within the TAV epitope of the E2 protein having the amino acid sequence TAVSPTTLR or, wherein the amino acid substitution within the TAV epitope of the E2 protein results in the TAV epitope sequence TAVSKDTLRT.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the CSFV vaccine is an attenuated vaccine, and/or, wherein the CSFV is a C (Chinese)-strain.

### Claim 17 (depends on 1)

A method of differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of claim 1, comprising
a. obtaining a sample from an animal, and
b. analyzing said sample in a immuno test and/or genomic analytical test.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the immuno test comprises testing whether antibodies specifically recognizing the intact TAV epitope (TAVSPTTLR) of the CSFV E2 protein are binding to the CSFV E2 protein in the sample.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the immuno test is an EIA (enzyme immunoassay) or ELISA (enzyme linked immunosorbent assay), or, wherein the genomic analytical test is a PCR (polymerase chain reaction), RT-PCR (reverse transcriptase polymerase chain reaction) or real time PCR (polymerase chain reaction).
